BTF3L4

Across TCGA pan-cancer cohorts, BTF3L4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BTF3L4 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BTF3L4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BTF3L4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, PDAC, and OV are the cancer types where BTF3L4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.898	1.000	.009	12	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	6	view →
OV	DFS	Median	All	0.869	1.000	.038	4	view →
LUAD	DFS	Median	III,IV	0.964	0.554	.015	3	view →
LSCC	DFS	Quartile	II,III,IV	0.831	0.310	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BTF3L4–CCRCC (DFS)

Open the CCRCC breakdown →